bosentan anhydrous has been researched along with Ischemia in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (21.74) | 18.2507 |
| 2000's | 9 (39.13) | 29.6817 |
| 2010's | 9 (39.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Firdolas, F; Karakeci, A; Ogras, MS; Orhan, I; Ozan, T; Unus, I | 1 |
| Akgun, B; Berilgen, SM; Demir, CF; Kaplan, M; Ozdemir, HH; Sarı, A | 1 |
| Dong, Q; Gong, S; He, X; Lv, J; Peng, L; Seng, Z; Wang, W; Yan, B | 1 |
| Görgülü, T; Guler, R; Kargi, E; Olgun, A; Torun, M | 1 |
| Brodmann, M; Gotschuli, G; Hafner, F; Siegel, C; Thonhofer, R | 1 |
| Matucci-Cerinic, M; Seibold, JR | 1 |
| Arrébola López, MA; Hernández, MM; Todoli Parra, JA | 1 |
| Alegre Sancho, JJ; Castillo, MJ; Egurbide, MV; Fonollosa, V; Lloria, X; Roman Ivorra, JA; Simeon, CP | 1 |
| Cervigón-González, I; Palomo-Arellano, A; Torres-Iglesias, LM | 1 |
| Hoffmann, U; Kuhn, A; Riemekasten, G; Sunderkötter, C; Weiss, N | 1 |
| Stern, PJ; Wall, LB | 1 |
| Cabane, J; Humbert, M | 1 |
| Black, C; Carpentier, P; Chatterjee, S; Coppock, J; Denton, CP; Furst, D; Gaitonde, M; Guillevin, L; Hachulla, E; Herrick, A; Hsu, V; Korn, JH; Matucci Cerinic, M; Mayes, M; Merkel, PA; Molitor, J; Nguyen, N; Peter, HH; Pope, J; Rainisio, M; Rich, E; Seibold, JR; Simms, R | 1 |
| Boullanger, N; Carpentier, P; Diot, E; Fain, O; Hachulla, E; Hatron, PY; Jego, P; Launay, D; Mouthon, L; Pasquier, E | 1 |
| Hall, FC; Ostor, AJ; Yu, EP | 1 |
| Li, XS; Pernow, J; Wang, QD | 1 |
| Giersch, B; Scommotau, S; Spiegel, HU; Uhlmann, D | 1 |
| McCartney, SA; Warner, TD | 1 |
| Alving, K; Goiny, M; Oldner, A; Rudehill, A; Sollevi, A; Wanecek, M; Weitzberg, E | 1 |
| Anadol, AZ; Bayram, O; Dursun, A; Ercan, S | 1 |
| Palmes, D; Spiegel, HU; Uhlmann, D; Uhlmann, S | 1 |
| Löffler, BM; Spiegel, HU; Uhlmann, D; Uhlmann, S; Witzigmann, H | 1 |
| Duriez, M; Henrion, D; Iglarz, M; Lévy, BI; Silvestre, JS | 1 |
2 review(s) available for bosentan anhydrous and Ischemia
| Article | Year |
|---|---|
Digital ulcers and outcomes assessment in scleroderma.
Topics: Bosentan; Fingers; Hand Dermatoses; Humans; Iloprost; Ischemia; Scleroderma, Systemic; Severity of Illness Index; Skin Ulcer; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2008 |
[Management of digital ulcers in patients with systemic sclerosis].
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Fingers; Humans; Iloprost; Ischemia; Male; Raynaud Disease; Risk Factors; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Vasodilator Agents | 2012 |
1 trial(s) available for bosentan anhydrous and Ischemia
| Article | Year |
|---|---|
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
Topics: Activities of Daily Living; Administration, Oral; Antihypertensive Agents; Bosentan; Disability Evaluation; Double-Blind Method; Endothelin Receptor Antagonists; Female; Fingers; Health Status; Humans; Ischemia; Male; Middle Aged; Scleroderma, Systemic; Severity of Illness Index; Skin Ulcer; Sulfonamides; Surveys and Questionnaires; Treatment Outcome | 2004 |
20 other study(ies) available for bosentan anhydrous and Ischemia
| Article | Year |
|---|---|
Second pathways in the pathophysiology of ischemic priapism and treatment alternatives.
Topics: Adenosine Deaminase; Animals; Antihypertensive Agents; Apoptosis; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Enzyme Inhibitors; Heme Oxygenase-1; Ischemia; Male; Penis; Priapism; Protoporphyrins; Purinergic P1 Receptor Antagonists; Random Allocation; Rats; Rats, Sprague-Dawley; Signal Transduction; Sulfonamides; Theophylline | 2013 |
Electrophysiological effects of bosentan in rats with induced cerebral ischemia-reperfusion.
Topics: Animals; Antihypertensive Agents; Bosentan; Brain Ischemia; Electroencephalography; Electrophysiological Phenomena; Female; Ischemia; Malondialdehyde; Neurons; Perfusion; Rats; Rats, Wistar; Reperfusion Injury; Sulfonamides | 2013 |
Bosentan protects the spinal cord from ischemia reperfusion injury in rats through vascular endothelial growth factor receptors.
Topics: Animals; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Gene Expression Regulation; Ischemia; Male; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Spinal Cord Injuries; Sulfonamides; Time Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Evaluation of the Effect of Bosentan-Mediated Endothelin Receptor Blockade on Flap Survival in Rats: An Experimental Study.
Topics: Animals; Bosentan; Endothelin Receptor Antagonists; Inflammation; Ischemia; Male; Neovascularization, Physiologic; Rats; Rats, Wistar; Re-Epithelialization; Sulfonamides; Surgical Flaps | 2016 |
Successful bosentan treatment of critical ischaemia induced by vasculitis in an SCLE patient.
Topics: Acute Disease; Adult; Antihypertensive Agents; Bosentan; Female; Humans; Ischemia; Leg; Lupus Erythematosus, Cutaneous; Sulfonamides; Vasculitis | 2008 |
Efficacy of bosentan in digital ischemic ulcers.
Topics: Aged; Bosentan; Endothelin Receptor Antagonists; Fingers; Humans; Ischemia; Magnetic Resonance Angiography; Male; Microscopic Angioscopy; Middle Aged; Plethysmography; Skin Ulcer; Smoking Cessation; Sulfonamides; Thromboangiitis Obliterans; Treatment Outcome; Vasodilator Agents | 2010 |
Bosentan in clinical practice for treating digital and other ischemic ulcers in Spanish patients with systemic sclerosis: IBER-DU cohort study.
Topics: Antihypertensive Agents; Bosentan; Cohort Studies; Humans; Hypertension; Ischemia; Randomized Controlled Trials as Topic; Retrospective Studies; Scleroderma, Systemic; Skin Ulcer; Spain; Sulfonamides; Treatment Outcome | 2011 |
Effectiveness of bosentan in the treatment of ischemic lesions in a case of thromboangiitis obliterans (Buerger disease): a case report.
Topics: Adult; Bosentan; Compassionate Use Trials; Endothelin Receptor Antagonists; Female; Humans; Ischemia; Skin Ulcer; Sulfonamides; Thromboangiitis Obliterans; Vasodilator Agents | 2011 |
Nonoperative treatment of digital ischemia in systemic sclerosis.
Topics: Bosentan; Botulinum Toxins, Type A; Calcium Channel Blockers; Education, Medical, Continuing; Endothelin Receptor Antagonists; Evidence-Based Medicine; Female; Fingers; Humans; Iloprost; Ischemia; Life Style; Middle Aged; Orthopedics; Phosphodiesterase 5 Inhibitors; Prostaglandins; Randomized Controlled Trials as Topic; Raynaud Disease; Scleroderma, Systemic; Sulfonamides; Vascular Resistance; Vasodilator Agents | 2012 |
Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan.
Topics: Bosentan; Endothelin Receptor Antagonists; Fingers; Humans; Hypertension, Pulmonary; Ischemia; Male; Middle Aged; Scleroderma, Systemic; Skin Ulcer; Sulfonamides | 2003 |
[Bosentan for treatment of active digital ulcers in patients with systemic sclerosis].
Topics: Adult; Aged; Antibodies, Antinuclear; Bosentan; Endothelin-1; Female; Fingers; Follow-Up Studies; Humans; Ischemia; Male; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Time Factors; Treatment Outcome | 2006 |
Successful treatment with bosentan for severe digital ischaemia in limited cutaneous systemic sclerosis.
Topics: Adult; Bosentan; Fingers; Humans; Ischemia; Male; Scleroderma, Limited; Sulfonamides; Vasodilator Agents | 2007 |
Beneficial effects of the endothelin receptor antagonist bosentan on myocardial and endothelial injury following ischaemia/reperfusion in the rat.
Topics: Animals; Blood Flow Velocity; Bosentan; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelins; Heart; Ischemia; Male; Rats; Rats, Sprague-Dawley; Reperfusion; Sulfonamides; Time Factors | 1995 |
Effect of the endothelin receptor antagonist bosentan on postischemic liver microcirculation.
Topics: Animals; Bosentan; Endothelin Receptor Antagonists; Female; Injections, Intravenous; Ischemia; Liver; Microcirculation; Rats; Rats, Wistar; Receptors, Endothelin; Sulfonamides; Vasoconstriction | 1996 |
Shock news for the gut.
Topics: Antihypertensive Agents; Bosentan; Cytokines; Endothelin Receptor Antagonists; Endothelin-1; Endotoxins; Humans; Intestinal Mucosa; Intestines; Ischemia; Shock, Septic; Sulfonamides; Time Factors | 1998 |
The endothelin receptor antagonist bosentan restores gut oxygen delivery and reverses intestinal mucosal acidosis in porcine endotoxin shock.
Topics: Acidosis; Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Escherichia coli; Intestinal Mucosa; Intestines; Ischemia; Lipopolysaccharides; Oxygen; Shock, Septic; Splanchnic Circulation; Sulfonamides; Swine | 1998 |
Role of endogenous endothelin peptides in intestinal ischemia-reperfusion injury in rats.
Topics: Animals; Bosentan; Dinoprostone; Endothelin Receptor Antagonists; Endothelins; Female; Glycopeptides; Histocytochemistry; Intestinal Mucosa; Intestines; Ischemia; Leukotriene C4; Male; Peptides, Cyclic; Rats; Reperfusion Injury; Sulfonamides | 1998 |
Endothelin receptor blockade as a therapeutic strategy in ameliorating postischemic damage to the liver microcirculation.
Topics: Animals; Bosentan; Endothelin Receptor Antagonists; Female; Ischemia; Liver; Liver Circulation; Microcirculation; Rats; Rats, Wistar; Reperfusion Injury; Sulfonamides | 2000 |
Pharmacological regulation of postischemic sinusoidal diameters in rats--a new approach for reducing hepatic ischemia/reperfusion injury.
Topics: Animals; Antihypertensive Agents; Blood Gas Monitoring, Transcutaneous; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelium, Vascular; Female; Ischemia; Liver; Microcirculation; Rats; Rats, Wistar; Reperfusion Injury; Sulfonamides; Vasoconstriction | 2001 |
Chronic blockade of endothelin receptors improves ischemia-induced angiogenesis in rat hindlimbs through activation of vascular endothelial growth factor-no pathway.
Topics: Animals; Antibodies; Bosentan; Capillaries; Endothelial Growth Factors; Endothelin Receptor Antagonists; Endothelin-1; Enzyme Inhibitors; Hindlimb; Ischemia; Lymphokines; Male; Neovascularization, Physiologic; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Radiography; Rats; Rats, Wistar; Receptor, Endothelin A; Signal Transduction; Sulfonamides; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |